Systemic Lupus Erythematosus (Lupus)

Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease in which the immune system generates antibodies that attack the body's own tissues, producing inflammation across multiple organ systems simultaneously. Understanding lupus requires familiarity with its disease classification, diagnostic criteria, immunological mechanisms, and clinical boundaries — particularly its overlap with other rheumatic conditions. This page covers the definition and scope of SLE, how the underlying immune dysfunction operates, the clinical scenarios in which it presents, and the decision boundaries that distinguish it from related disorders.

Definition and scope

Systemic lupus erythematosus affects an estimated 1.5 million people in the United States, according to the Lupus Foundation of America. It is classified as a systemic autoimmune connective tissue disease, meaning its pathology is not confined to a single organ but can involve the skin, kidneys, joints, central nervous system, cardiovascular system, lungs, and blood.

The American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) jointly published updated classification criteria in 2019 — the 2019 EULAR/ACR Classification Criteria for SLE. Under this framework, a positive antinuclear antibody (ANA) test serves as the mandatory entry criterion, with additional weighted criteria across 7 clinical domains and 3 immunological domains. A total score of 10 or more points classifies a patient as having SLE.

SLE disproportionately affects women, with a female-to-male ratio of approximately 9:1 (National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIAMS). The disease onset peaks between ages 15 and 44. African American, Hispanic, Asian, and Native American women face higher prevalence rates and more severe disease courses compared to non-Hispanic white women, a disparity documented by NIAMS.

Lupus does not belong to a single diagnostic category — there are four recognized subtypes:

  1. Systemic lupus erythematosus (SLE) — the most common and severe form, involving multiple organ systems
  2. Cutaneous lupus — limited primarily to skin manifestations, including discoid lupus erythematosus (DLE)
  3. Drug-induced lupus — triggered by specific medications such as hydralazine, procainamide, and isoniazid; resolves upon drug discontinuation
  4. Neonatal lupus — a rare condition in newborns of mothers with anti-Ro/SSA or anti-La/SSB antibodies

For a broader view of how lupus fits into the spectrum of autoimmune disease across rheumatology, the overview at /index situates SLE within the full landscape of rheumatologic conditions.

How it works

SLE arises from a failure in central and peripheral immune tolerance. The core mechanism involves defective clearance of apoptotic cell debris, which leads to the accumulation of nuclear antigens. Autoreactive B cells and T cells — which should be eliminated during immune development — escape deletion and begin producing autoantibodies targeting nuclear components.

The hallmark autoantibody in SLE is anti-double-stranded DNA (anti-dsDNA), found in approximately 70% of SLE patients (NIAMS). Anti-Smith (anti-Sm) antibodies are highly specific for SLE. These autoantibodies form immune complexes that deposit in tissues including the glomerular basement membrane of the kidney, triggering complement activation and sustained inflammatory injury.

The complement pathway plays a central role in SLE pathology. Immune complex deposition activates the classical complement pathway (C1q, C2, C4), leading to the consumption of complement proteins. Measured as reduced C3 and C4 serum levels, complement consumption is both a diagnostic marker and a monitor of disease activity. The relationship between complement testing and disease monitoring is covered in depth at Complement Levels and Autoantibody Panels.

Interferon-alpha dysregulation amplifies the autoimmune response. Plasmacytoid dendritic cells produce abnormally elevated levels of type I interferons in response to immune complexes containing nucleic acids, creating a chronic inflammatory loop that sustains tissue damage.

Organ damage in SLE is driven by two parallel processes: acute inflammatory injury from immune complex deposition and ischemia from antiphospholipid antibodies, which promote thrombosis in both venous and arterial circulation.

Common scenarios

SLE presents across a wide spectrum of severity and organ involvement. The following structured breakdown captures the dominant clinical presentations encountered in rheumatology practice:

  1. Musculoskeletal presentation — Arthritis or arthralgia occurs in up to 95% of SLE patients over the disease course (ACR). Unlike rheumatoid arthritis, SLE arthritis is typically non-erosive and migratory.
  2. Cutaneous presentation — The malar (butterfly) rash over the cheeks and nasal bridge, sparing the nasolabial folds, is present in approximately 50% of patients. Photosensitivity rashes and oral ulcers are additional skin-mucosal manifestations.
  3. Lupus nephritis — Kidney involvement affects 40–60% of SLE patients and represents one of the most serious complications (National Kidney Foundation). The 2021 ACR/EULAR classification of lupus nephritis defines six histological classes based on renal biopsy findings.
  4. Neuropsychiatric SLE (NPSLE) — Manifestations include seizures, psychosis, cognitive dysfunction, and cerebrovascular events. The ACR defined 19 distinct neuropsychiatric syndromes attributable to SLE in its 1999 nomenclature document.
  5. Hematologic involvement — Cytopenias, including autoimmune hemolytic anemia, leukopenia (white blood cell count below 4,000/mm³), and thrombocytopenia (platelet count below 100,000/mm³), are scored under the 2019 EULAR/ACR criteria.
  6. Serositis — Pleuritis and pericarditis occur in roughly 25% of patients and may be the presenting feature in older-onset SLE.
  7. Antiphospholipid syndrome overlap — Approximately 30–40% of SLE patients test positive for antiphospholipid antibodies, increasing thrombotic and pregnancy complication risk.

Patients living with this condition over time face a distinct set of management challenges described at Living with Lupus. Pregnancy in SLE warrants specialized evaluation, addressed at Pregnancy and Rheumatic Disease.

Decision boundaries

Distinguishing SLE from overlapping autoimmune conditions requires systematic application of diagnostic criteria, not symptom pattern alone. The following comparisons define the key decision boundaries in clinical rheumatology:

SLE versus rheumatoid arthritis (RA): Both conditions cause symmetric polyarthritis and can produce positive ANA tests. RA is distinguished by erosive joint disease on imaging, elevated anti-CCP antibodies, and the absence of multi-system involvement. SLE arthritis is characteristically non-erosive. Anti-dsDNA and anti-Sm antibodies are absent in RA. The diagnostic boundary between these conditions is covered at Anti-CCP and Rheumatoid Factor and Rheumatoid Arthritis.

SLE versus Sjögren's syndrome: Both conditions produce anti-Ro/SSA and anti-La/SSB antibodies and share fatigue, arthralgia, and ANA positivity. Primary Sjögren's syndrome is defined by sicca symptoms (dry eyes, dry mouth) with glandular lymphocytic infiltration on biopsy, without the multi-organ systemic features characteristic of SLE. Secondary Sjögren's syndrome can occur alongside SLE. Distinctions are detailed at Sjögren's Syndrome.

SLE versus drug-induced lupus (DIL): Drug-induced lupus mimics SLE with arthritis, serositis, and ANA positivity, but anti-dsDNA antibodies are typically absent. Anti-histone antibodies are present in over 90% of DIL cases. Symptoms resolve within weeks to months of drug discontinuation. Kidney and central nervous system involvement is rare in DIL, making organ-specific workup essential.

SLE versus undifferentiated connective tissue disease (UCTD): Patients presenting with ANA positivity, fatigue, and mild features of connective tissue disease who do not fulfill 2019 EULAR/ACR criteria for SLE are classified as UCTD. Longitudinal follow-up is required, as approximately 20–30% of UCTD cases evolve into a defined connective tissue disease, most commonly SLE, over 5 years (European League Against Rheumatism guidance).

The regulatory context for rheumatology provides the framework within which SLE diagnosis and treatment are governed at the federal and clinical guideline level, including FDA-approved therapeutic classifications relevant to biologic treatments such as belimumab (approved by the FDA in 2011 as the first new lupus-specific drug in over 50 years

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)